An experimental drug currently being tested against breast and lung cancer shows promise in fighting the brain cancer glioblastoma and prostate cancer, researchers at UT Southwestern Medical Center have found in two preclinical studies.
The drug’s actions, observed in isolated human cells in one trial and in rodents in the other, are especially encouraging because they attacked not only the bulk of the tumor cells but also the rare cancer stem cells that are believed to be responsible for most of a cancer’s growth, said Dr. Jerry Shay, professor of cell biology and a senior co-author of both papers. The
The ‘White Room’ at Meyer pediatric hospital in Florence needs to complete a few more procedures to become completely functional. This stem cell and cellular product ‘factory’ will allow cells to be manipulated for therapies used in bone marrow treatments against leukemia and tumors and in reconstructive medicine to reproduce bone, cartilage, fat, and nervous tissue in metabolic and neurological diseases and treatments for serious autoimmune disorders.
“The certification procedures are very long,” explained the head of transfusions and cellular therapy, Franco Bambi, “because we will be considered a pharmaceutical manufacturing facility, but we are planning to finish the
Researchers at Queen Mary, University of London, studied equivalent cells taken from mouse brains. Principal investigator Silvia Marino, Professor of Neuropathology at Queen Mary, University of London, and her team showed that medulloblastomas can grow from a type of brain stem cell and that these cancers are a distinct form of the disease which may require a completely different approach to treatment.
Like a Hole in the Head: Living with a Brain Tumour
Image via Wikipedia
Taming the bad cancer stem cells, genetically modifying them to arm them against disease and cancer-from defusing the bomb. Bet on cell girls ‘GM’, transformed into cancer killer bullets, one of five projects funded by AIRC (Italian Association for Cancer Research) with 60 million in five years thanks to the funds of 5 per thousand.
Studies of molecular oncology clinic, chosen by a jury of 18 super-foreign experts, who share one big final goal: to train a new generation of physicians, researchers are able to bridge the gap between the lab bench and the bedside. In five years’
Novogen Limited, an oncology drug development company, today announced a collaboration with Australian company, Genea Biocells, to accelerate testing of their super-benzopyran (SBP) drugs for degenerative diseases of the nervous system and muscles.
Preliminary research conducted by both companies found that super-benzopyrans appear to be effective at promoting the ‘normalization’ of stem cells associated with some forms of neurodegeneration and muscular dystrophy, genetic disorders which result in progressive deterioration of brain function or muscle strength and function.
“SBPs have already been shown to be highly effective at killing cancer stem cells, which were previously considered resistant to anti-cancer therapy.
But in some